ATLANTA—At the 2017 American Society of Hematology Annual Meeting, Aileron Therapeutics made two oral presentations regarding preclinical data on ALRN-6924 in T cell lymphomas (TCL) and acute myeloid leukemia (AML). In TCL, a preclinical in-vitro and in-vivo study showed that when targeting MDMX and MDM2, ALRN-6924 induced apoptotic cell death in tumor lines and significantly reduced tumor burden compared to vehicle. The compound also had a positive safety profile and superior efficacy compared to the existing standard of care. In AML, preclinical data demonstrated that disrupting MDMX/p53 and MDM2/p53 interactions generated strong anti-leukemic effects as well as cell cycle arrest and apoptosis in cell lines and wild-type p53 AML patients' cells. ALRN-6924 showed strong on-target activity in AML cell lines and primary cells in vitro and in a treated patient.